Análise de longo prazo de estudo randomizado de fase 2 | Fulvestrante com capivasertibe vs. placebo após recorrência ou progressão do inibidor de aromatase no câncer de mama metastático, positivo para receptor de estrogênio e negativo para HER2.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial – The Lancet Oncology

Comunicado de imprensa: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University

Estudo original: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial – The Lancet Oncology